×
About 1,230 results

ALLMedicine™ Factor X Center

Research & Reviews  450 results

Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740962
PloS One; Traets MJM, Nijhuis RHT et. al.

Jan 8th, 2022 - Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest with varying disease severity and mortality. Genetic predisposition influences the clinical course of infectious diseases...

A Review of Coagulation Abnormalities of Autoimmune Acquired Factor V Deficiency with a...
https://doi.org/10.1055/s-0041-1740149
Seminars in Thrombosis and Hemostasis; Ichinose A, Osaki T et. al.

Dec 24th, 2021 - Coagulation factor V (or FV for the purpose of medical safety) is an essential cofactor of coagulation factor X in the common pathway of coagulation; severe FV deficiency leads to a bleeding tendency. Although both congenital and acquired FV defic...

The functional role of the autolysis loop in the regulation of factor X upon hemostatic...
https://doi.org/10.1111/jth.15624
Journal of Thrombosis and Haemostasis : JTH; Bonde AC, Lund J et. al.

Dec 21st, 2021 - The regulation of factor X (FX) is critical to maintain the balance between blood coagulation and fluidity. To functionally characterize the role of the FX autolysis loop in the regulation of the zymogen and active form of FX. We introduced novel ...

Stoichiometric analysis reveals a unique phosphatidylserine binding site in coagulation...
https://doi.org/10.1111/jth.15620
Journal of Thrombosis and Haemostasis : JTH; Paul D, Morrissey JH

Dec 12th, 2021 - Cellular trauma or activation exposes phosphatidylserine (PS) and the substantially more abundant phospholipid, phosphatidylethanolamine (PE), on the outer layer of the plasma membrane, thereby allowing binding of many blood clotting proteins. We ...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  11 results

Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
https://clinicaltrials.gov/ct2/show/NCT04499612

Sep 23rd, 2021 - 250 patients of similar age, gender, and ethnicity will be divided into five groups: Group A1-3: 150 patients with indications for cardiac implantable electronic device (CIED) implantation; Group B: 50 patients with an CIED implanted 8-10 years ag...

Pediatric Intensive Care and COVID-19
https://clinicaltrials.gov/ct2/show/NCT04544878

Sep 10th, 2020 - All patients will be monitored during their PICU stay. Clinical characteristics include: age, gender, co-morbidities, organ support therapies (mechanical ventilation, renal replacement therapy, extracorporeal membrane oxygenation, vasopressors), o...

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery
https://clinicaltrials.gov/ct2/show/NCT01086852

Feb 5th, 2019 - To investigate the safety and efficacy of FACTOR X administered by bolus infusion to prevent bleeding and achieve haemostasis in factor X deficient subjects undergoing surgery.

Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
https://clinicaltrials.gov/ct2/show/NCT02568696

Mar 29th, 2018 - Background In clinical kidney transplantation organ retrieval, cold-preservation of the graft as well as restoration of the blood flow to the transplant cause tissue damage (ischemia/reperfusion injury). Clinically these events can manifest themse...

Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux
https://clinicaltrials.gov/ct2/show/NCT00378027

Jan 27th, 2017 - The current standard therapy for Acute Pulmonary Embolism (APE) involves admitting patients to the hospital for administration of parenteral anticoagulation therapy(Unfractionated Heparin, Low Molecular Weight Heparin, or Fondaparinux) as a bridge...

see more →

News  26 results

Andexanet alfa effectively reverses factor Xa inhibition
https://www.mdedge.com/cardiology/article/196564/stroke/andexanet-alfa-effectively-reverses-factor-xa-inhibition
Erik Greb

Mar 18th, 2019 - HONOLULU – Andexanet alfa rapidly reverses factor Xa inhibition and effectively establishes hemostasis in patients with acute major bleeding, according to a study presented at the International Stroke Conference sponsored by the American Heart Ass.

Emicizumab beats factor VIII prophylaxis by a wide margin
https://www.mdedge.com/internalmedicine/article/173787/bleeding-disorders/emicizumab-beats-factor-viii-prophylaxis-wide
Will Pass

Aug 30th, 2018 - In patients with hemophilia A who do not have factor VIII inhibitors, emicizumab therapy outperformed factor VIII prophylaxis, according to a results of a randomized, open-label, phase 3 trial. Crystal/Wikimedia Commons/Creative Commons Attributio.

Emicizumab granted priority review for hemophilia A without inhibitors
https://www.mdedge.com/hematology-oncology/article/184916/thrombosis/emicizumab-granted-priority-review-hemophilia-without-inhibitors
HT Staff

Jun 7th, 2018 - By Crystal (Crystl) from Bloomington, USA - Flickr Bleeding human finger The US Food and Drug Administration (FDA) has granted priority review for emicizumab (Hemlibra®) for adults and children with hemophilia A without factor VIII inhibitors. Ear.

Emicizumab receives breakthrough designation
https://www.mdedge.com/hematology-oncology/article/185010/thrombosis/emicizumab-receives-breakthrough-designation
HT Staff

Apr 18th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to emicizumab (Hemlibra®) for patients who have hemophilia A without factor VIII inhibitors. Emicizumab is a bisp.

Product approved for hemophilia patients in Japan
https://www.mdedge.com/hematology-oncology/article/185054/thrombosis/product-approved-hemophilia-patients-japan
HT Staff

Mar 27th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the bispecific factor IXa- and factor X-directed antibody emicizumab (Hemlibra), according to Chugai Pharmaceutical Co. , Ltd.

see more →